$31.75
-0.29[-0.91%]
Last update: 1:16PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
$32.04
0.2900[0.91%]
| Open31.920 | Close- |
| Vol / Avg.36.532K / 175.347K | Mkt Cap941.806M |
| Day Range31.590 - 32.265 | 52 Wk Range31.170 - 59.960 |
Keros Therapeutics Stock (NASDAQ:KROS), Key Statistics
Keros Therapeutics Stock (NASDAQ: KROS) analysis, key statistics.
Valuation Measures
Enterprise Value
642.3M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
2.91
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-14.17%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
11
Tangible Book value per share
11
Total Liabilities (Quarterly)
30M
Total Assets
356.3M
Total Liabilities
30M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Keros Therapeutics Stock (NASDAQ:KROS), Key Statistics
Keros Therapeutics Stock (NASDAQ: KROS) analysis, key statistics.
Valuation Measures
Enterprise Value
642.3M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
2.91
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-14.17%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
11
Tangible Book value per share
11
Total Liabilities (Quarterly)
30M
Total Assets
356.3M
Total Liabilities
30M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Keros Therapeutics Stock (NASDAQ:KROS), Key Statistics
Keros Therapeutics Stock (NASDAQ: KROS) analysis, key statistics.
Valuation Measures
Enterprise Value
642.3M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
2.91
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-14.17%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
11
Tangible Book value per share
11
Total Liabilities (Quarterly)
30M
Total Assets
356.3M
Total Liabilities
30M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Keros Therapeutics Stock (NASDAQ:KROS), Key Statistics
Keros Therapeutics Stock (NASDAQ: KROS) analysis, key statistics.
Valuation Measures
Enterprise Value
642.3M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
2.91
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-14.17%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
11
Tangible Book value per share
11
Total Liabilities (Quarterly)
30M
Total Assets
356.3M
Total Liabilities
30M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Keros Therapeutics Stock (NASDAQ:KROS), Key Statistics
Keros Therapeutics Stock (NASDAQ: KROS) analysis, key statistics.
Valuation Measures
Enterprise Value
642.3M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
2.91
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-14.17%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
11
Tangible Book value per share
11
Total Liabilities (Quarterly)
30M
Total Assets
356.3M
Total Liabilities
30M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Keros Therapeutics Stock (NASDAQ:KROS), Key Statistics
Keros Therapeutics Stock (NASDAQ: KROS) analysis, key statistics.
Valuation Measures
Enterprise Value
642.3M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
2.91
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-14.17%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
11
Tangible Book value per share
11
Total Liabilities (Quarterly)
30M
Total Assets
356.3M
Total Liabilities
30M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Keros Therapeutics Stock (NASDAQ:KROS), Key Statistics
Keros Therapeutics Stock (NASDAQ: KROS) analysis, key statistics.
Valuation Measures
Enterprise Value
642.3M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
2.91
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-14.17%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
11
Tangible Book value per share
11
Total Liabilities (Quarterly)
30M
Total Assets
356.3M
Total Liabilities
30M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Keros Therapeutics Stock (NASDAQ:KROS), Key Statistics
Keros Therapeutics Stock (NASDAQ: KROS) analysis, key statistics.
Valuation Measures
Enterprise Value
642.3M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
2.91
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-14.17%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
11
Tangible Book value per share
11
Total Liabilities (Quarterly)
30M
Total Assets
356.3M
Total Liabilities
30M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -
Keros Therapeutics Stock (NASDAQ:KROS), Key Statistics
Keros Therapeutics Stock (NASDAQ: KROS) analysis, key statistics.
Valuation Measures
Enterprise Value
642.3M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
- -
Price / Book (mrq)
2.91
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-14.17%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
11
Tangible Book value per share
11
Total Liabilities (Quarterly)
30M
Total Assets
356.3M
Total Liabilities
30M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
- -
EBIT Margin
- -
EBITDA Margin
- -
Operating Margin
- -